Hi all
pretty new to all this. I have pumped some into Deltex - looks like a strong product with good growth. Could be a steady gainer.
Does anyone else have this, and anyone have some research on it? Someone with more experience than me!
thanks in advance.
Grajul

THE COUNT--->GREEKMAN

Despite the problems with the NHS, they are still by far the largest user of oesophaegeal doppler for fluid optimisation on the planet and, despite cash constraints, DEMG sales to them are increasing by about 25% pa.

Imagine what could happen if the purse strings were loosened a little to start fulfilling some of that pent up clinical demand (UK doctors that want to use the probes NOW but can't get finance for them) that is running at about a factor of 10 above actual present sales.

And whatever we say about the UK and its attitude to technology, the UK, as DEMG keep on telling me, is the world leader in the use of haemodynamic optimisation.

What we should now have, is the UK model rolled out into the USA and Europe as well. We wil get there eventually, either at a bit more than snail's pace, or some single catalyst could really make this one explode.

Regards,

THE COUNT!

Hi Count,
Fully agree. It is mainly the next couple of years I was referring to. This is when I feel the percentage of use of the doppler in the NHS will drop compared to the rest of the world, even allowing for a steady NHS use increase.
The UK has always been know as a world leader in many innovations. A huge percentage of these new products, technologies don't get the backing they deserve and end up taking off (because of foreign money) in these other countries. The UK then play catch up.
May be too early to judge, but already looking like another good day for the sp.

Cheers Greek

Duplicate Post

THE COUNT--->GREEKMAN

The following article in THE INDEPENDENT may just have something to do with it. Well, I doubt it will have harmed it.

The broker Charles Stanley reiterated its "strong buy" advice on Deltex Medical Group after Tuesday's preliminary decision to reimburse doctors their time and for the use of the company's blood fluid monitoring system. The broker believes that the ruling could be "company transforming" in the longer term as there is now an incentive for doctors to use the product, which has been clinically proved. The broker believes that the company could get taken over at anywhere between 50p and 100p. Despite the note, the stock closed a quarter of a penny worse at 17.5p.


Regards,

THE COUNT!

Usually take brokers advice with a good pinch of salt, but in this case all the indications are there.
I saw their report and the bit ,"that the ruling could be "company transforming" in the longer term says it all.
I would think the institutions will be keeping a keen eye on this and hopefully those already in will increasing their holdings. Also be nice to see others jumping on board.

THE COUNT--->ALL

The analyst at Charles Stanley has updated a paragraph in his guidance note yesterday which should excite most of you pop pickers out there.

Here are his words verbatim....


Why this may be transformational.

Prior to this announcement, we had considered that the long term potential for the Group was excellent based on the premise that market penetration would gradually increase and that revenues could increase by around 30% compound. That assumed that the status quo would be maintained and that the market penetration in the USA would also increase gradually. However, in the first public consultation period, although there were only four comments from physicians, these were all positive. In particular, twp physicians stated that, in their view, the Deltex ODM was more efficient and safer to use than the pulmonary artery catheter which is in common use in the US as physicians receive substantial sums in reimbursement for its use. One physician stated that he was able to optimise patients for some surgeries to the point that ICU (Intensive Care Unit) care was no longer the routine but the exception. As the ICU is expensive, that should lead to substantial savings for medical insurers.

With evidence such as this, we consider reimbursement (because of the potential savings) could be significant and that growth in the US from 2008 could be faster than we had anticipated. We also consider that the possibility of a large medical device company wishing to acquire the group has been increased.

We reiterate our Strong Buy opinion to clients who understand the risks of investing in small companies.



There, that reads pretty well on such a horrible day in the markets, doesn't it?

Regards,

THE COUNT!

I've been looking at this lot. Could be one for the SIPP for me.

The Count,

Seeing the initial brokers note from Charles Stanley made me more positive that ever re Deltex's future, now having seen the update I am just waiting for lift off.
This share is looking to be an excellent prospect.
Thanks for the post.

Cheers Greek.

Hi greekman News of a meeting in London.. Deltex are pulling out all the stops to get their product name in the frame...

Deltex are to hold a public meeting where it will demonstrate the latest prototype of the entirely non-invasive SupraQ haemodynamic monitor.

The meeting will take place at 12 noon on Tuesday 6 March in the Southampton
Suite of the Radisson Edwardian Grafton Hotel at 130 Tottenham Court Road. The full report can be found at www.shareclubuk.co.uk

There will also be a short presentation on the developments in the USA announced on 27 February from Deltex Medical's Chief Executive, Andy Hill, at the end of the meeting, attendees will have the opportunity to have their own haemodynamic status measured with the SupraQ.

myway

Myway,

Thanks for the info. I would like to attend the presentation but unfortunately I am unable to,due to business, but no doubt reports will be around soon after the 6th.
Things progressing nicely.

Bid/Offer gone from 17/17.50 to 17.50/19 that a large jump, maybe a buyer in the wings or mm's just increased it prior to the presentation this pm.
2517

Presentation went well by the look of sp.
2517

Barclays have upped their stake. OK only by a tad but an increase all the same.

Deltex Medical Plc.. The meeting on Tuesday 6th March of last week has a positive effect on the companys share price which has traded up. Details on the movement can be found at www.shareclubuk.co.uk race to profits page. On the back of the good weeks news Barclays Shareholders Ltd and Gerrard Ltd, now hold 4,515,383 of the issued share capital. 5.60% of the voting rights. This is indeed a step in the right direction.

With reference to the US Government HTA Published paper.
Tried to wade through this huge document, decided to see what Deltex and Analysts say, as it requires a lot of time to study. After a very quick scan through nothing adverse sprang out.
No doubt that by Market close those with the time and expertise will have come to a conclusion and hopefully the sp will reflect their opinions (upward).
The institutions will be pouring through this mammoth paper asap.

As for the results, all indication are that everything looks to be on track.
A nice steady increase in profits, mainly from repeat customers.

The next 12 months are looking to be a very important to Deltex.

Early in the day yet, but Level 2 looking good, about to tick up.
End of day should be interesting.

Deltex Medical Plc.. Preliminary results for the year ended 31 December 2006

Financial Highlights

Turnover increased by 15% to pound;3,511,000 with 80% of growth from recurring revenue streams
Operating losses increase to pound;2,102,000 (2005: pound;1,774,000) after TECO acquisition and restructuring of European distribution network
Cash of pound;418,000 with a further pound;465,000 of new equity raised since year end
Company enters 2007 with lowest rate of cash burn and operating loss
since first listing

Operating Highlights

All regions show sustainable growth driven by recurring probe revenues
Steady stream of evidenced based research supports new monitoring
applications
SupraQ adopted by Medway Maritime Hospital for critical care
applications; enhanced prototype SupraQ completed in 2007
Accelerating uptake from a range of reference customers including
European teaching hospitals and US military
Medicare proposed reimbursement approval lays ground for accelerated
penetration of USA
Company configured for growth in all its key markets

For the reader of this thread a full report on view at www.sharecluuk.co.uk

Looks like Charles Stanley & Co Ltd (Rock Nominees Limited) are now on board with 4,851,121 a 5.8% stake. Surprised the sp is down ,although have not seen the budget yet so don't know if that has had any effect or not.

Looks like the todays news release is just reaffirming in simple speak what the very lengthy document of last week was telling us. CardioQ is good for the patient.
SP did not move on this release due to I expect, punters treating it as yet another positive result. When the medical world wakes up to this excellent piece of kit, no doubt the investors will also. Staying well into this share for that almost certain take off day.

Hi greekman

Key conclusions from the US report

The HTA concluded that in 'patients undergoing surgical procedures with an
expected substantial blood loss or fluid compartment shifts requiring fluid
replacement' the clinical evidence for ODM was strong in respect of the
following three statements:

1. 'Doppler-guided fluid replacement during surgery leads to a clinically
significant reduction in major complications';

2. 'Doppler-guided fluid replacement during surgery leads to a clinically
significant reduction in the total number of complications'; and

3. 'Doppler-monitored fluid replacement leads to a reduction in hospital
stay'.

The full report and other news can be found at www.shareclubuk.co.uk for members and others to view.. Over the next few weeks the S.P. should firm up. This US report will help matters along